MA-PRESS-GANEY/FORSTA
27.4.2022 15:02:07 CEST | Business Wire | Press release
Press Ganey , renowned leader in patient, member, employee and consumer experience across the healthcare ecosystem, announced it has completed its acquisition of Forsta , a leading global provider of market research, customer experience (CX) and employee experience (EX) technology. The closing is effective as of April 26, 2022.
As industry-recognized leaders, with Press Ganey recently selected Best in KLAS for Patient Experience Improvement and Forsta named a Leader in the 2021 Gartner® Magic Quadrant™ for Voice of the Customer , the combined companies will power the future of research and experience technology.
“Together, Press Ganey and Forsta offer our clients the data connectivity, accelerated analytics, DEI expertise and deeply segmented insights that companies need to deliver frictionless experiences and truly drive transformation,” said Patrick T. Ryan, chairman and chief executive officer, Press Ganey. “With Forsta, we expand into new geographies and industries, with highly complementary market research, CX and EX technology that will coordinate seamlessly with our existing healthcare solutions.”
“Press Ganey is expediting Forsta’s mission to reinvent the global insights industry. With this investment, we will be able to greatly accelerate innovation so our customers can deliver better insights, faster and at scale,” said Kyle Ferguson, chief executive officer, Forsta. “There is tremendous opportunity from the convergence of our resources, and we have no plans to slow down.”
Acquisition Highlights
Fast-tracked Product Innovation. Press Ganey’s investment will advance Forsta’s product innovation at an accelerated pace, especially in the high-demand areas of artificial intelligence (AI), data visualization and qualitative research.
Marketplace Expansion. Forsta’s global presence and extensive network will propel Press Ganey’s international healthcare growth ambitions while also expanding the company into new verticals, such as retail, financial services and consumer goods.
Unparalleled Insights. Both companies are proven changemakers and bring proprietary research and thought leadership to deliver key insights that tackle essential issues, like barriers to human-centered data , employee burnout and advancing health equity .
Healthcare Sector Disruption. Backed by blue-chip consulting, unparalleled experience measurement expertise and proprietary analytics to help drive improvement, Press Ganey will offer breakthrough advancements to the evolving healthcare marketplace. A new suite of purpose-built for healthcare, self-service solutions are immediately available, like digital communities, virtual focus groups, crowdsourcing and more.
Exceptional Human Capital. Two empowered, elite workforces will come together around aligned missions and pursuits to seamlessly turn data into meaningful insights that drive impact.
The joint company will continue to be led by Ryan as chairman and CEO, and Ferguson will remain at the helm of Forsta as CEO. Combined, the organization’s 3,000+ employees now serve thousands of customers, including Fortune 500 companies and top healthcare systems, throughout the North America, EMEA (Europe-Middle East-Africa) and APAC (Asia-Pacific) regions.
About Press Ganey
Press Ganey invented the healthcare performance improvement movement over 35 years ago. Today it offers an integrated suite of solutions that address safety, clinical excellence, patient experience and workforce engagement. The company works with more than 41,000 healthcare facilities in its mission to reduce patient suffering and enhance caregiver resilience to improve the overall safety, quality and experience of care.
About Forsta
Forsta powers an Experience and Research Technology Platform that gathers and analyzes data, and translates the findings into shareable actions to inform decision-making and drive growth. Forsta’s technology, combined with its team of expert consultants, help organizations better understand the full Human Experiences (HX) of their audiences.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220413005008/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press release
Barilla continues to advance its commitment to tastier products with less sugar and salt;An investment of 30 million euros in 2025 to quadruple photovoltaic capacity across plants, as part of a €168 million five-year plan focused on energy efficiency, renewable energy and sustainable water management.Barilla continues to expand regenerative agriculture practices across its global value chain, with over 816,000 tons of raw materials sourced through the Barilla Sustainable Farming program.4,000 tons of products donated worldwide and €2 million allocated to social causes in 2025, supporting communities across Barilla’s global footprint through food donations and social initiatives. A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal oppor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom